Nomura Holdings
CRSP icon

Nomura Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Nomura Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982K Buy
18,000
+9,500
+112% +$501K ﹤0.01% 1360
2026
Q1 		$404K Buy
+8,500
New +$448K ﹤0.01% 1427
2025
Q2 		– Sell
-30,000
Closed -$1.02M – 1555
2025
Q1 		$1.02M Buy
+30,000
New +$1.27M ﹤0.01% 1271

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nomura Holdings's CRSP Position: Q2 2026 in Review

Nomura Holdings increased its CRISPR Therapeutics (CRSP) stake by 963% in Q2 2026, buying an estimated $2.68M and bringing the position to 56,027 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Nomura Holdings first reported a position in CRSP in Q4 2023 and has held it in 4 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Nomura Holdings held 56,027 shares of CRISPR Therapeutics worth $3.06M as of Q2 2026.
  • Nomura Holdings bought 50,754 CRISPR Therapeutics shares in Q2 2026, an estimated $2.68M.
  • CRISPR Therapeutics made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #950 holding.
  • Nomura Holdings first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.